| Biologic properties of homogeneous interleukin 3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity … JN Ihle, J Keller, ST Oroszlan, LE Henderson, TD Copeland, F Fitch, ... Journal of immunology (Baltimore, Md.: 1950) 131 (1), 282-287, 1983 | 969 | 1983 |
| Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. K Hestdal, FW Ruscetti, JN Ihle, SE Jacobsen, CM Dubois, WC Kopp, ... Journal of immunology (Baltimore, Md.: 1950) 147 (1), 22-28, 1991 | 582 | 1991 |
| Procedures for the purification of interleukin 3 to homogeneity. JN Ihle, J Keller, L Henderson, F Klein, E Palaszynski Journal of immunology (Baltimore, Md.: 1950) 129 (6), 2431-2436, 1982 | 550 | 1982 |
| Bcl11a is essential for normal lymphoid development P Liu, JR Keller, M Ortiz, L Tessarollo, RA Rachel, T Nakamura, ... Nature immunology 4 (6), 525-532, 2003 | 430 | 2003 |
| Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature S Seaman, Z Zhu, S Saha, XM Zhang, MY Yang, MB Hilton, K Morris, ... Cancer cell 31 (4), 501-515. e8, 2017 | 357 | 2017 |
| Transforming growth factor beta is a potent inhibitor of interleukin 1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. CM Dubois, FW Ruscetti, EW Palaszynski, LA Falk, JJ Oppenheim, ... The Journal of experimental medicine 172 (3), 737-744, 1990 | 291 | 1990 |
| Transforming growth factor beta 1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines. JR Keller, C Mantel, GK Sing, LR Ellingsworth, SK Ruscetti, FW Ruscetti The Journal of experimental medicine 168 (2), 737-750, 1988 | 285 | 1988 |
| Transforming growth factor beta selectively inhibits normal and leukemic human bone marrow cell growth in vitro GK Sing, JR Keller, LR Ellingsworth, FW Ruscetti | 271 | 1988 |
| Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow … P Tiberghien, CW Reynolds, J Keller, S Spence, M Deschaseaux, ... | 246 | 1994 |
| Transforming growth factor beta directly regulates primitive murine hematopoietic cell proliferation JR Keller, IK Mcniece, KT Sill, LR Ellingsworth, PJ Quesenberry, GK Sing, ... | 234 | 1990 |
| Transcriptome analysis of mouse stem cells and early embryos AA Sharov, Y Piao, R Matoba, DB Dudekula, Y Qian, V VanBuren, ... PLoS biology 1 (3), e74, 2003 | 226 | 2003 |
| Interleukin 3: possible roles in the regulation of lymphocyte differentiation and growth JN Ihle, L Rebar, J Keller, JC Lee, AJ Hapel Immunological reviews 63 (1), 5-32, 1982 | 215 | 1982 |
| Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation C Berthet, KD Klarmann, MB Hilton, HC Suh, JR Keller, H Kiyokawa, ... Developmental cell 10 (5), 563-573, 2006 | 206 | 2006 |
| Phenotypic characteristics of cell lines requiring interleukin 3 for growth. JN Ihle, J Keller, JS Greenberger, L Henderson, RA Yetter, HC Morse 3rd Journal of immunology (Baltimore, Md.: 1950) 129 (4), 1377-1383, 1982 | 194 | 1982 |
| Steel factor (c-kit ligand) promotes the survival of hematopoietic stem/progenitor cells in the absence of cell division JR Keller, M Ortiz, FW Ruscetti | 188 | 1995 |
| The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation B Asefa, KD Klarmann, NG Copeland, DJ Gilbert, NA Jenkins, JR Keller Blood Cells, Molecules, and Diseases 32 (1), 155-167, 2004 | 178 | 2004 |
| Distinct regions of the interleukin-7 receptor regulate different Bcl2 family members Q Jiang, WQ Li, RR Hofmeister, HA Young, DR Hodge, JR Keller, ... Molecular and cellular biology 24 (14), 6501-6513, 2004 | 175 | 2004 |
| C/EBPα deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo V Heath, HC Suh, M Holman, K Renn, JM Gooya, S Parkin, KD Klarmann, ... Blood 104 (6), 1639-1647, 2004 | 165 | 2004 |
| JAK2 is associated with the c-kit proto-oncogene product and is phosphorylated in response to stem cell factor SR Weiler, S Mou, CS DeBerry, JR Keller, FW Ruscetti, DK Ferris, ... | 150 | 1996 |
| Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. SF Stinson, MC Alley, WC Kopp, HH Fiebig, LA Mullendore, AF Pittman, ... Anticancer research 12 (4), 1035-1053, 1992 | 150 | 1992 |